Advertisement

Breast Cancer Research and Treatment

, Volume 165, Issue 3, pp 783–784 | Cite as

Response Letter

  • M. Brezezinska
  • L. J. Williams
  • J. Thomas
  • J. M. DixonEmail author
Rebuttal Letter
  • 101 Downloads

Editor,

Rosso and colleagues are correct that BCT remains controversial in IBC, but they note that our management is consistent with the recommendations of the UK IBC Working Group although contrary to earlier expert panels. Rosso and colleagues use data from NSABP B-18 to argue that BCT would produce an unacceptable rate of LR failure in IBC. Our study showed that in very carefully selected patients (21 out of 139 IBC from January 2005 to December 2013 had BCT) there was no evident excess of LR failure. Data soon to be published identified 150 patients with IBC from the SEER database treated by BCT and this study likewise showed no detriment to outcome. [1] In a multivariate analysis of a cohort of over 3000 women with patients with IBC treated included in this study, surgical treatment was not a significant prognostic factor for Breast Cancer-Specific or Overall survival. Rosso and colleagues accept that IBC is rare but suggest that BCT should be limited to a trial. We accept that...

References

  1. 1.
    Chen H, Wu J, Wang M, Wang F, Zhang M, Zhang P (2017) A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: a large population-based study in the surveillance, epidemiology and end results database 18. Breast 35:48–54CrossRefGoogle Scholar
  2. 2.
    Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A (2016) Neoadjuvant endocrine therapy for estroegn receptor positive breast cancer: a systematic review and meta-analysis. JAMA Oncol 2(11):1477–1486CrossRefGoogle Scholar
  3. 3.
    Dixon JM, Love CDB, Renshaw L, Bellamy C, Cameron DA, Miller WR, Leonard RCF (1999) Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 6:227–230CrossRefGoogle Scholar
  4. 4.
    Dixon JM (2015) Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with breast cancer. Breast Cancer Manag 4(6):271–274CrossRefGoogle Scholar
  5. 5.
    Berrocal J, Saperstein L, Grube B, Horowitz NR, Chapgar AB, Killelea BK, Lannin DR (2017) Intraoperative injection of technetium-99 m sulphur colloid for sentinel lymph node biopsy in breast cancer patients: a single institution experience. Surg Res Pract. Doi:  10.1155/2017/5924802 https://www.hindawi.com/journals/srp/2017/5924802/abs/
  6. 6.
    Dixon JM (2016) Sentinel lymph node biopsy in breast cancer surgery. Ann Surg Oncol 23(11):3426–3428CrossRefGoogle Scholar
  7. 7.
    Hidar S, Bibi M, Gharbi O, Tebra S, Travelsi A, Korbi S, Bouaouina N, Ben Ahmed S, Khairi H (2009) Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg 7(3):272–275CrossRefGoogle Scholar
  8. 8.
    Stearns V, Ewing CA, Slack R et al (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9(3):235–242CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • M. Brezezinska
    • 1
  • L. J. Williams
    • 1
  • J. Thomas
    • 1
  • J. M. Dixon
    • 1
    Email author
  1. 1.Edinburgh Breast UnitWestern General HospitalEdinburghUK

Personalised recommendations